Plans to launch an experimental prostate cancer pill have been put onhold after it failed to improve survival rates in a late-stage clinicaltrial.
Biopharmaceutical company AstraZeneca will now go back to the drawingboard and plans no regulatory submissions for zibotentan after testingrevealed that it failed to improve overall survival rates in the PhaseIII study.
This latest setback comes after similarly unsuccessful trials for twoother AstraZeneca pills – Recentin in colon cancer earlier this yearand vandetanib in lung cancer in 2009.
Zibotentan, a once-daily tablet, is being studied in more than 3,000men with prostate cancer in a programme of clinical trials, while twoother studies which are exploring other potential uses for the drug arestill ongoing.
Copyright Press Association 2010